Emerging therapeutic approaches for vitiligo are under investigation and target multiple immune pathways, including IFN-γ inhibitors, CXCL10/CXCR3 antagonists, Janus kinase (JAK) inhibitors, PD-1/PD-L1 modulation, and HSP70i DNA-based therapies (117). Here, CD274 is linked to vitiligo.